ReviewBioactive materials2026
Programmable next-generation supramolecular self-assembled materials as drug delivery systems.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Structure-Guided Design of an Interface-Derived Inhibitor Peptide Against Spodoptera frugiperda Digestive Trypsins.Archives of insect biochemistry and physiology · 2026Article
- A Review on Recent Progress and Clinical Translation of Self-Assembled Hydrogels in Diabetic Wound Repair.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Supramolecular self-assembly, driven by noncovalent interactions, serves as a fundamental principle for constructing complex functional systems (biological membranes, proteins, and DNA). Inspired by these natural paradigms, biomimetic self-assembly strategies have promoted the development of drug delivery systems (DDSs), including liposomes, lipid nanoparticles (LNPs), and virus-like particles. While these nanomedicines are clinically established, they continue to face persistent challenges, including maintaining drug stability and activity, achieving targeted delivery, overcoming biological barriers, and ensuring efficient intracellular release. Overcoming these obstacles requires the rational design of next-generation drug delivery materials. In this review, a comprehensive analysis of supramolecular self-assembled materials (SAMs) is provided. It traces the development and self-assembly mechanisms of SAMs. It defines the characteristics of next-generation SAMs, centered on their programmability, and focuses on introducing the innovative design strategy guidelines for next-generation SAMs. These guidelines fully embody the high programmability, precise size/morphology control capabilities, and multifunctional properties of SAMs. Furthermore, it discusses the latest application progress of SAMs in treating various diseases, and emphasizes the future strategies and challenges of SAM-based DDSs, aiming to facilitate broader clinical applications and benefit human health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.